Histopathology and immunohistochemistry of pancreatic islets in fibrocalculous pancreatic diabetes.
The histopathology of Fibrocalculous Pancreatic Diabetes (FCPD) has been extensively studied, but there are no reports on alteration in patterns of hormone secreting cells using immunohistochemistry in islets of FCPD patients. In this study, we report on the histopathology and immunohistochemistry of islets of FCPD patients and its possible correlation with the clinical picture. Pancreatic biopsies were carried out in six patients with FCPD at the time of surgery for abdominal pain. Routine histopathology and immunohistochemistry studies were carried out with six primary antibodies namely insulin, glucagon, pancreatic polypeptide (PP), somatostatin, vasoactive intestinal peptide and gastrin. Histopathology of the pancreas showed a spectrum of changes ranging from moderate to severe atrophy, fibrosis of the parenchyma and degeneration of the ducts. Nesidioblastosis was present in three patients. Immunohistochemical studies showed a decrease in the number of islets but some patients showed evidence of hyperplasia. There was an overall decrease in the percent of insulin cells and the positivity in the islets correlated with plasma C-peptide levels and the duration of diabetes. There was no consistent relationship with glucagon with some patients showing increased and other decreased positivity. There was a marked decrease in PP and somatostatin positivity, the significance of which is not clear. The reduction, but partial preservation of insulin positivity is consistent with the ketosis resistance shown by patients with Fibrocalculous Pancreatic Diabetes.
Govindarajan
M
M
R&D Histopathological Laboratory, 600 004, Chennai, India.
Mohan
V
V
Deepa
R
R
Ashok
S
S
Pitchumoni
C S
CS
D000293:Adolescent; D000328:Adult; D001284:Atrophy; D001706:Biopsy; D001786:Blood Glucose / Q000032:analysis; D002908:Chronic Disease; D003920:Diabetes Mellitus / Q000097:blood / Q000473:pathology*; D005260:Female; D005755:Gastrins / Q000032:analysis; D005934:Glucagon / Q000032:analysis; D006801:Humans; D006965:Hyperplasia; D007150:Immunohistochemistry; D007328:Insulin / Q000032:analysis; D007515:Islets of Langerhans / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010179:Pancreas / Q000473:pathology*; D010183:Pancreatic Ducts / Q000473:pathology; D010191:Pancreatic Polypeptide / Q000032:analysis; D010195:Pancreatitis / Q000097:blood / Q000473:pathology*; D014660:Vasoactive Intestinal Peptide / Q000032:analysis
D001786:Blood Glucose; D005755:Gastrins; D007328:Insulin; D014660:Vasoactive Intestinal Peptide; D010191:Pancreatic Polypeptide; D005934:Glucagon